Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes

Diabetes, Obesity and Metabolism

Volumn 4, Issue 4, 2002, Pages 255-261

  Pan, J ^a   Lin, M ^a   Kesala, R L ^a   Van, J ^a   Charles, M A ^a  

^a Diabetes Research Center   (United States)

Author keywords

Atherogenic lipid profile; Diabetic dyslipidaemia; Lp(a); Niacin

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; LIPID;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUSHING; HUMAN; HYPOTHESIS; LIPID ANALYSIS; MALE; METABOLIC DISORDER; PATIENT COMPLIANCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRURITUS; RASH; ULCER; VOMITING; ARTERIOSCLEROSIS; BLOOD; CLINICAL TRIAL; DIABETIC ANGIOPATHY; RETROSPECTIVE STUDY; RISK FACTOR;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; LIPIDS; LIPOPROTEIN(A); NIACIN; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 0035991486     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2002.00205.x     Document Type: Article

References (36)

1. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarctions
2. Arrhythmias and mortality after myocardial infarction in diabetic patients
3. The Scandinavian simvastatin survival study (4S) group. cholesterol lowering with simvastatin improves prognosis of diabetic patients with CHD
4. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial
5. Beyond LDL cholesterol reduction
6. The artherogenic lipid profile is associated with type 2 diabetes and some of its treatment modalities
7. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes
8. Optimization of glycemic control by insulin therapy decreases the proportion of small, dense LDL particles in diabetic patients
9. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults
10. Small, dense LDL particles as a predictor of the risk of ischemic heart disease in men
11. Role of plasma triglyceride in the regulation of plasma (LDL) subfractions relative contribution of small, dense LDL to coronary heart risk
12. New aspects of cardiovascular risk factors including small, dense LDL, homocysteinemia, and Lp (a)
13. Lipoprotein Lp (a) excess and CHD
14. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid
15. Effectiveness of once-nightly dosing of extended-release niacin alone and in combimation for hypercholesterolemia
16. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial
17. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford coronary risk intervention project
18. Differential effects of nicotinic acid in subjects with different LDL subclass patterns
19. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
20. Management of dyslipidemia in adults with diabetes
21. The successful treatment of the atherogenic lipid profile (ALP; Small, Dense LDL, HDL2, HDLc and Triglycerides) and Lp(a) in diabetic patients (DP) using niacin
22. Effect of niacin in lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease
23. Lipid and Lipoprotein Analysis
24. Dextran sulfate-Mg precipitation procedure for quantitation of high-density lipoprotein cholesterol
25. Detection and quantitation of LDL subfractions
26. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles
27. Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men
28. Current and future trends in therapy for dyslipidemias
29. Troglitazone and small low-density lipoprotein in type 2 diabetes
30. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia
31. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects
32. Atorvastatin (A), although minimally increasing LDL size does reduce small, dense LDL particle mass similar to niacin (N) and niaspan (NS) in diabetic patients
33. Niacin and atorvastatin monotherapies, and combination treatment of the atherogenic lipid profile in diabetes mellitus
34. High dose atorvastatin therapy in women with diabetic dyslipidemia
35. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
36. Extended release niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes